Cargando…
A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response...
Autores principales: | De Divitiis, Chiara, von Arx, Claudia, Carbone, Roberto, Tatangelo, Fabiana, Di Girolamo, Elena, Romano, Giovanni Maria, Ottaiano, Alessandro, de Lutio di Castelguidone, Elisabetta, Iaffaioli, Rosario Vincenzo, Tafuto, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386800/ https://www.ncbi.nlm.nih.gov/pubmed/25878507 http://dx.doi.org/10.2147/OTT.S71025 |
Ejemplares similares
-
Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
por: Capozzi, Monica, et al.
Publicado: (2019) -
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016) -
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021) -
Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
por: von Arx, Claudia, et al.
Publicado: (2019) -
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019)